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Summary Human epithelial ovarian tumours were successfully established as xenografts in nude mice in
54% of cases. An evaluation of the biological characteristics of tumours propagated in nude mice was carried
out and the functions investigated included morphology, growth kinetics, cellular DNA content, cell surface
antigen expression and sensitivity to chemotherapy. To allow a more detailed study of the influence of ploidy
on biological behaviour, xenografted tumour with varying degrees of aneuploidy and tumours with a common
ancestry but different ploidies were also established. Although this is a highly selective model system
favouring the growth of biologically aggressive tumours the xenografts, in general, reflect many of the
characteristics of the tumours from which they were derived and are likely to provide a useful model for
investigating the biology of ovarian cancer.
The development of the congenitally athymic mouse
mutant has provided a host that supports growth of
human malignant tumours and offers unique
possibilities to study the biology of human tumours
in vivo. Of paramount importance in assessing the
value of the xenograft model has been the
evaluation of biological characteristics of tumours
propagated in nude mice compared to those of the
parent (donor) tumour. The general consensus
reached in a number of studies encompassing a
variety of tumour types is that human tumour
xenografts largely reflect the features of the donor
tumour with the exception of proliferation kinetics
and metastatic properties (for reviews see
Shimosata et al., 1982; Povlsen et al., 1982).
However, there have been few detailed studies on
the utility of ovarian tumour xenografts (Davy et
al., 1977; Kullander et al., 1978; Teufel et al., 1981;
Van Haaften Day et al., 1983). The aims of this
study were two fold, firstly to investigate biological
characteristics of ovarian tumour xenografts
compared with those of the original tumour from
which they were established, and secondly to
establish a model system of xenografted tumours
with different ploidies. Results of clinical flow
cytometric studies have indicated that cellular DNA
content is of prognostic importance in ovarian
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epithelial tumours (Friedlander et al., 1984a, b) as
well as in a number of other tumour types (for
review see Friedlander et al., 1984c) yet the
fundamental reasons for this remain obscure.
Establishment of diploid ovarian tumours together
with tumours with varying degrees of aneuploidy in
nude mice would allow more detailed study of the
possible relationship between tumour ploidy and
biological behaviour.
Materials and methods
Ovarian tumour xenografts
Establishment andmaintenance ofxenografts Female
BALB/c nude mice were obtained from the
Australian Atomic Energy Commission, Lucas
Heights, NSW, and housed in laminar flow racks
and provided with sterilised food and drinking
water ad libitum. Sterilised gloves, clean gowns, face
masks and caps were used when handling the
animals.
Tumour tissue was obtained directly from the
operating theatre under sterile conditions, placed in
RPMI 1640 medium containing 10% foetal calf
serum and dissected into fragments measuring 3-
5mm in diameter. A sample was set aside for flow
cytometry and histology. Xenografts were
established in 6 week old mice by inoculating these
fragments s.c., using fine forceps, through a small
incision in the scapular region of the mouse. The
incision was sutured with fine silk, a procedure
which improved the take rate by ensuring
fragments remained in place. Bilateral implantation
was performed in all instances under ether
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anaesthesia. Depending on the size of tumour
sample obtained 3-5 mice were used in the attempt
to establish xenografts.
When establishing xenografts from ascites or
from in vitro cell lines, -5 x 107 cells were injected
s.c. in 0.1-0.2ml of medium. The effusions were
collected under sterile conditions, centrifuged at
200g for 10min in 50ml propylene centrifuge tubes
(Corning Glass Company, Corning, NY) and the
pellet resuspended in phosphate buffered saline
(PBS) and washed twice prior to inoculation.
A tumour "take" was defined as a tumour which
grew progressively after implantation and could be
serially passaged. In the event of no growth
occurring 8 months-1 year after implantation of the
original tumour from the patient, the mice were
sacrificed and this was defined as negative take.
When the tumours reached a size of 10-15mm in
diameter they were serially passaged by s.c.
implantation of explants of xenografted tissue as
described above. At this time samples of tissue were
taken for flow cytometry and also fixed in
combined formalin, acetic acid and alcohol (FAA)
for subsequent histological examination. Autopsies
were performed on most of these mice and
specimens fixed in FAA for histological
examination if there was macroscopic evidence of
metastasis.
Growth characteristics Tumours were measured
weekly, when they achieved a size of 3-5mm in
diameter, using graduated calipers. Growth curves
were expressed as tumour size versus time, where
the area (mm2) was calculated by using the formula
for an ellipse,
dl d2
7 +--x 2 2
with dl and d2 representing the maximum
diameters of the tumour measured at right angles
(Teufel et al., 1981).
Median tumour size was plotted against time and
the doubling time (TD) found by interpolation on a
semi-logarithmic plot (Steel et al., 1983). The time
taken for control and treated tumours to double in
size (area) was determined and the difference (TD
treated-TD control) was taken to approximate the
growth delay. In order to allow comparison in
delay values between tumour types that vary widely
in growth rate, the specific growth delay was used
to estimate the number of doubling times saved by
treatment. (It should be noted that area doubling
times are somewhat longer than volume doubling
time.)
TD treated-TD control specific growth delay=- TD control
Flow cytometry Flow cytometric analysis of DNA
content and proliferative fraction was performed,
using a rapid staining technique previously
described (Taylor, 1980; Friedlander et al., 1983),
on all primary tumour specimens, after most
routine passages of "stock" tumours and on
tumours implanted for chemosensitivity testing.
Regional heterogeneity with respect to ploidy and
S phase fraction in xenografted tumours was
investigated by sampling tissue from tumour areas
with different vascularisation. The vascularity of
tumours was determined by injecting mice i.p. with
0.2-0.3ml of a 2% solution of Lissamine green.
This non-toxic dye colours the animal green in
about an hour and the colour begins to fade in a
few hours. Lissamine green delineates various areas
within a tumour with the well vascularised regions
staining deep green and avascular regions remaining
white (Goldacre & Sylven, 1959). Tumour
samples/fine needle aspirates from differently
staining areas were then taken and prepared for
flow cytometric analysis.
Chemotherapy A series of experiments was
conducted to study the chemosensitivity of
xenografted tumour and compared with the results
of treatment in the donor patient. Standard criteria
for response were used for assessing the response to
treatment in patients (Miller et al., 1981).
Single agent chemotherapy was given by
intraperitoneal injection, the therapeutic dosage
being determined in a series of toxicity experiments
by treating groups of 5 mice with varying dose
levels. The maximum tolerated dose (MTD) was
used and defined as the drug dose that caused
<20% decrease in body weight and did not kill
any mice.
The final doses used in chemosensitivity testing
were as follows:
Cisplatinum 5mgkg l i.p. weekly x 4.
Melphalan 5mgkg i.p. weekly x 4.
Drugs were freshly made up for each experiment.
Control animals were treated with normal saline (in
the case of cisplatinum treatment) or with
melphalan diluent (in the case of melphalan
therapy) in an equivalent volume, and control and
test tumour growth curves were compared. In the
majority of experiments there were 5 animals in the
treated and control groups. Tumours were
measured weekly using calipers, as described earlier.
Histology
Specimens for histological examination were taken
from the tumours destined for implantation and
also from the resulting xenograft. Tissues wereOVARIAN TUMOUR XENOGRAFTS 321
routinely fixed in FAA both for cytomorphology
and immunocytochemical staining.
Immunocytochemical staining was performed
using the immunoperoxidase technique described.
The antigens investigated included; CA, a putative
cancer specific antigen (Ashall et al., 1982); CA125,
a Mullerian differentiation antigen (Kabawat et al.,
1983); EMA, an epithelial membrane antigen
(Heyderman et al., 1979); and the oncofoetal
antigens alphafoetoprotein (AFP) and carcino-
embryonic antigen (CEA).
Immunocytochemical techniques The basic immuno-
peroxidase technique is outlined below with
modifications according to the particular antibody
used.
Steps:
1. Dewax 7pm paraffin section in xylene.
2. Remove xylene in absolute ethanol (3
changes of 2min each).
3. Block endogenous peroxidase activity by
incubating sections in 0.3% hydrogen
peroxide in methanol for 20min.
4. Rinse in tap water followed by Tris buffered
saline (pH 7.6).
5. Stand in non-immune swine serum for at
least 2min to reduce background staining.
6. Incubate sections in primary antibody for 1 h
(see below for details).
7. Wash slides in Tris buffer (pH 7.6) x 3.
8. Rinse quickly in non-immune swine serum.
9. Incubate sections with secondary antibody
(usually swine anti-rabbit immunoglobin 1:50
dilution) for 15min.
10. Wash slides in Tris buffer (pH7.6) x 3.
11. Rinse quickly in non-immune swine serum.
12. Incubate sections for 15min at room
temperature with PAP complex raised in
rabbit, diluted 1:100.
13. Rinse x 3 with Tris buffer.
14. Cover with freshly prepared diamino-
benzidine (DAB), to develop peroxidase
reaction, for 0min (DAB 40mg% in
phosphate bufferpH6.8 with25plH202/100ml
of buffer added immediately prior to use).
15. Wash well in tap water.
16. Counterstain with haematoxylin for 5min.
17. Rinse in water.
18. Differentiate in Acid Alcohol (1% HCL in
70% alcohol).
19. Blue in running warm water.
20. Dehydrate through ethanol and mount.
Modifications according to antibody used
CA1 The CA1 monoclonal antibody (Wellcome
diagnostics) was purchased as freeze dried residue
of 2ml of tissue culture fluid containing 25Mg of
CA1 antibody, 10% foetal calf serum and 0.1%
sodium azide as preservative. Sections were
incubated in the primary anti CA1 antibody
(dilution 1:100) for 16h at 4°C (Step 6). This was
followed by an additional step-exposure to rabbit
anti-mouse IgM (Miles Laboratories) at a dilution
of 1:500 for 15min. The rest of the procedure from
Step 7 was carried out as outlined above.
OC125 OC125 is a mouse IgG, monoclonal
antibody that was a gift from Dr R.C. Bast (Dana
Faber Cancer Institute, Boston). The method used
by Bast et al. (1983) to demonstrate the CA125
antigen was an indirect immunofluorescence
technique on cryostat sections of ovarian tissue
(Kabawat et al., 1983). The technique was modified
to allow detection of the CA125 antigen in FAA or
formalin-fixed, paraffin-embedded tissues. Sections
were incubated in OC125 antibody at a dilution of
1:100 for 16h at 4°C (Step6). This was followed by
an additional linking step by exposure of sections
to rabbit anti-mouse immunoglobulin (DAKO)
diluted 1:5000 for 15min. The rest of the procedure
from Step 7 onwards was performed as outlined
above.
Carcinoembryonic antigen: (CEA) Spleen absorbed
CEA (DAKO) was used at a dilution of 1: 500
(Step 6).
Alphafoetoprotein: (AFP) AFP (DAKO) was used
at a dilution of 1: 500 (Step 6).
Epithelial membrane antigen: (EMA) Sections were
incubated in goat EMA (SERA-LAB) at a dilution
of 1: 500 for 16h at 4°C (Step 6). This was followed
by a linking step using rabbit anti-goat (DAKO) at
a dilution of 1:100. The rest of the procedure is
outlined from Step 7 onwards, except that goat
PAP (DAKO) was used instead of rabbit PAP
(Step 12).
Controls
Known positive and negative tissue sections were
included to exclude false positives and negatives
which could arise due to technical problems.
Negative controls for OC125 included incubating
slides with Tl1, a purified mouse IgG1 pan T cell
antibody and also by omitting OC125 from the
staining procedure. In the ovarian xenografts the
primary monoclonal antibody was also omitted and
the sections incubated in the presence of the rabbit
anti-mouse antibody alone to confirm that there
was no nonspecific staining of tumour tissue.322 M.L. FRIEDLANDER, et al.
Results
Tumourigenicity ofovarian tumours in nude mice
Twenty-three epithelial ovarian tumours and 3
cultured ovarian carcinoma lines were implanted in
nude mice and progressive growth was evident in 16
cases (67%). Fourteen tumours were serially
passaged giving an overall successful take rate of
54%. Table I outlines details of the donor tumours,
that were implanted directly from the patient.
Advanced stage tumours had a higher likelihood of
a successful tumour take compared with early stage
(F.I.G.O. Stages I and II) tumours (P=0.01; x2
9.64). The advanced tumours (F.I.G.O. Stage III)
were invariably aneuploid, usually poorly
differentiated and in four instances tumours were
obtained from patients at the time of recurrence. In
contrast, borderline tumours and early stage
malignant ovarian cancers were associated with a
low likelihood of being successfully transplanted
and were commonly diploid (Table I). There also
appeared to be a relationship between tumour take
and patient survival: 60% of patients associated
with a successful tumour take died of ovarian
cancer, compared with 10% of patients where the
tumour did not take.
Growth ofovarian tumours in nude mice
The mean delay from initial implantation to the
first passage was 14 weeks (range 5-36 weeks)
(Table II). The time between subsecfuent passages
of stock tumours was quite variable and depended
predominantly on the size of tumour fragments that
were initially implanted and the size of the stock
tumours attained when the mice were sacrificed. In
general, 2 mm x 2 mm tumour fragments were
implanted and the tumours passaged when they
reached a size of 10-15mm in diameter.
Growth rates of the xenografted tumours were
determined by weekly caliper measurements of
groups of 8-10 tumours. Mean area (size) doubling
time (TD) was determined in 10 xenograft lines to
be 14 days (range 5-35 days). The mean take rate
Table I Details of ovarian tumours implanted directly in nude mice
Patient
Ploidy Sphase survival
Tumour Stage Type Grade (DI) (%) Take (Weeks)
VBa 1 E 3 1 11.6 - 140A
JL 1 E 1 1 5 - 20A
JH 1 M (LPM) 1 8.9 - 44A
RL 1 M (LPM) 1 5.5 - 40A
SG 1 S 1 4.3 - 60A
FF 1 E 2 1 15 + 80A
EB 1 C - 3.3 - 72A
MC 1 E 3 1 7.9 - 80A
MA 1 (REC) S 1 1.1 - 50A
AMa 1 CS - 1.68 18.5 + b 104A
SH 2 E 2 1.2 - 72A
PP 2 E 3 2 21.5 + 72A
DDa 2 (REC) S 3 1.9 25 + 156A
JM 3 S 3 1.72 16.8 + 75A
CC 3 S 3 2.60 25 + 72D
JC 3 (REC) S 3 1.35 + ID
EHa 3 S 3 1.64 16.9 + 26D
jVa 3 S 2 0.86 + 56D
NWa 3 S 3 0.8 + b 70D
NFa 3 CS - 1.47 24.7 + 12D
Hpa 3 S 3 1.45 25 + 52LTF
DO 3 S 2 1.33 21.8 + lDC
BR 3 (REC) S 3 1.53 - 20D
S =serous; E =endometrioid; M =mucinous; C=clear cell; CS=carcinosarcoma; LPM =low potential
malignancy; REC=recurrent tumour.
aTumours implanted at LICR by C. Van Haaften Day; A=alive; D=dead; LTF=lost to follow up.
bFailed to grow in subsequent passage.
'Post operative death. Table does not include the 3 tumours estimated from ovarian carcinoma cells in
culture (GG, JN, JV2). DI=DNA index, this represents the ratio of the DNA content of tumour G1 cells to
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Table II Time between initial implantation and subsequent passages, the take rate and tumour doubling time in
xenografted lines
Timefrom primary
implant to P1 Time between subsequent Take rate TD
Tumour (weeks) passages (weeks) % (days)
PP 5 8-12 83 5 (P2)
DD 10 12-16 80 7 (P6)
JN P12a 6-12 >90 5 (P8)
JC 9 8-12 90 9 (P2)
JV1 26 12-14 80 21 (P6)
JV2 12a 12 70 28 (P1)
NF 6 4-4 >90 7 (P4)
GG1 20a 12-20 >90 8 (P4)
GG2 8-18 >90 7 (P11)
FF 16 24 50 35 (P2)
DO 12 12-24 ND ND
JM 12 16 ND ND
CC 12 > 12 ND ND
JP 20 14-24 ND ND
EH 29 16-20 ND ND
aEstablished from tissue culture; ND=not determined - tumours maintained in 2 stock animals; (P)=passage
in which doubling time, TD, determined. Take refers to the number of tumours that grew progressively and the %
take in the Table refers to the mean % take for each particular tumour for all the passages it has been through.
of these lines in subsequent passages was 81% with
the lowest take rate of 50% occurring in the diploid
line (Table II).
Morphology andfunction ofovarian xenografts
Transplanted tumours grew locally at the site of
implantation and were strictly confined to the
subcutaneous space. They did not invade
surrounding soft tissues and could be readily
dissected from the adjacent dermis and fascia.
Metastatic spread was observed in only one slowly
growing tumour (DO) which metastasised to the
lungs during its first passage. The pulmonary
metastases closely resembled the histopathological
features of the original tumour. Whether this is a
consistent feature of this particular tumour is not
known as yet and is being investigated.
The majority of tumours grew as solid nodules,
but in some cases there were large areas of cystic
degeneration noted. The degree of vascularity
varied among tumour types with some tumours
being relatively avascular while others showed
prominent neovascularisation mainly from axillary
vessels. Haemorhagic necrosis occurred when such
tumours grew beyond 10-15mm in diameter.
The cytomorphology of the original tumours
were usually maintained following xeno-
transplantation although there were often minor
differences in architecture presumably due to a
different stromal reaction. There was no evidence
of increased differentiation occurring in any of the
tumours, the majority of the original tumours were
poorly differentiated (Grade III) and remained so in
subsequent passages. Three tumours (FF, JV, DO)
were moderately well differentiated when initially
implanted and have maintained their morphology
(Figure la,b), but they have been through only few
passages to date. In contrast those tumours which
had been initially established in cell culture and
passaged up to 14 times before being implanted
became progressively less differentiated following
xenografting (Figure ic).
Expression ofcell surface antigens
The expression of a number of antigenic deter-
minants was compared in xenografted tumours and
the corresponding original (donor) tumour where
adequate well fixed tissue was available for im-
munocytochemistry. Antigens investigated included
the epithelial membrane antigen (EMA), the CA
antigen, the CA125 antigen and the oncofoetal
antigens, alphafoetoprotein (AFP) and carcino-
embryonic antigen (CEA). The results of the study
are outlined in Table III and disclose no
appreciable differences in the expression of these
antigens between the xenografted and donor
tumours (Figure 2). The patterns and distribution
of staining of EMA, CA1 and OC12%were similar in
the xenografted tumour tissue although, there was a
greater degree of cytoplasmic staining present,324 M.L. FRIEDLANDER, et al.
Figure 1 (a) Morphology of moderately differentiated serous carcinoma (JV) before xenografting ( x 250); (b)
Morphology of moderately differentiated serous carcinoma after xenografting (JV1, passage 7) ( x 250); (c)
Morphology of JV2 xenograft (P1). This was established from a cell line (OC:JV2) obtained by growing the
original JV tumour in tissue culture. Undifferentiated carcinoma exhibiting cell to cell variation and nuclear
anaplasia. This tumour became more aneuploid during cell culture and had a modal chromosome number of
64.
Table III Expression of cell surface antigens in the original and xenografted ovarian tumours
CA, OC125 EMA CEA AFP
Tumour Passage Histology PT XN PT XN PT XN PT XN PT XN
JV1 6 Serous + + + + + +
JV2a 1 Serous + + + + + + - - _ b
JN 5 Serous ND + ND + ND+ - - - -
JC 1 Serous + + + + + +
EH 2 Serous + + + + + +
CGa 7 Clear cell + + + - + +
JM 1 Serous + + + + + +
DO 1 Serous + + + + + +
PP 1 Adenosquamous - - - - + b +b - +b +b
JP 1 Serous ND + ND + ND +
FF 1 Endometrioid - + + + + +
NF 1 Carcinosarcoma - -
DD 6 Serous - - - - + +
+ = >100% of cells stain positively; ± = <10% of cells stain; -=no detectable staining.
aEstablished from cultured line; b=adenocarcinoma cells only stain; ND=not done; PT=donor tumour; XN=
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particularly for CA . In all tumours studied, apart
from one carcinosarcoma, both the parent and
xenografted tumour were EMA positive. A feature
of most tumours analysed for reactivity with OC125
and CA1 was a variability in staining between
otherwise morphologically indistinguishable cells.
This heterogeneity in cell surface antigen expression
was maintained in the xenografted tumours. The
expression of CEA and AFP was also compared in
the xenografted and respective original tumours to
investigate their stability. However, apart from a
single case where AFP could be demonstrated in a
Figure 2 Comparison of EMA staining in (a) original serous carcinoma and (b) after xenografting ( x 200).326 M.L. FRIEDLANDER, et al.
few scattered cells in both the original and
xenografted tumour (PP), they were all CEA and
AFP negative.
The in Situ response ofxenografts to chemotherapy
The responses of 8 ovarian xenografted tumour
lines to treatment with cisplatinum and melphalan
are shown in Table IV and Figure 3. Although
chlorambucil was used in patients, melphalan was
chosen in preference to treat the xenografts because
of the availability of a commercial preparation
suited for i.p. injection. The mechanisms of action
of melphalan and chlorambucil are similar and
comparable response rates for each drug have been
reported in ovarian cancer (for review, see
Tattersall, 1981).
Patient JV had an unresectable Stage III serious
carcinoma and was treated with a combination of
cisplatinum and chlorambucil with a good partial
response and minimal residual pelvic tumour was
clinically evident after 4 months of therapy. She
relapsed however, 3 months later while still on
treatment and eventually died with drug resistant
disease. The JV1 line, established directly from this
patient, responded completely to cisplatinum and
melphalan with no evidence of regrowth occurring
during a 6 week period of observation. In contrast,
the JV2 line which was established in the xenograft
only after being propagated in tissue culture did
not respond to cisplatinum or melphalan. This
carcinoma was histologically less well differentiated
than JV1 and has approximately twice its cellular
DNA content.
Patient NF had an extremely aggressive and
widely metastatic carcinosarcoma which did not
respond to a combination of chlorambucil and
provera and the patient died with progressive
disease within 3 months of diagnosis. The
xenografted tumour grew rapidly and was totally
resistant to cisplatinum and melphalan.
Patient PP had a Stage Ilc adenosquamous
carcinoma that was completely resected and she
then received a combination of cisplatinum for 8
courses together with cyclophosphamide for 1 year.
She remains well and with no evidence of disease 18
Table IV Effect of chemotherapy on ovarian tumour xenografts
Tumour Treatment Passage treated TD (days) Growth delay
DD+ Control P6 7
Cisplatinum 6/8 CR
Melphalan 10/10 CR
PP Control P2 5
Cisplatinum 5 0
Melphalan 21 3.2
JNa+ Control P8 5
Cisplatinum 8/10 CR
Melphalan 5 0
JC+ Control P2 9
Cisplatinum 32 2.5
Melphalan 22 1.4
JV1 Control P6 21
Cisplatinum 9/10 CR
Melphalan 7/10 CR
JV2a Control Pi 28
Cisplatinum 24.5
Melphalan 28 0
NF Control P4 7
Cisplatinum 6 0
Nelphalan 7 0
GGIa+ Control P4 8
Cisplatinum 17 1.1
Melphalan 16 0.875
CR=complete regression, indicates complete disappearance of a tumour for a
period of observation of up to 10 weeks, at which time the mice were sacrificed.
aXenograft established from cell line; + =xenograft established from recurrent
tumour.OVARIAN TUMOUR XENOGRAFTS 327
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Figure 3 The effects of therapy with cisplatinum (P) and melphalan (M) in 8 different ovarian tumour lines
growing in nude mice. Animals were injected i.p. with drugs or vehicle in the case of control animals (C) at
weekly intervals x 4 commencing week 1.
months after diagnosis. In the xenografted tumour
cisplatinum was ineffective, but melphalan resulted
in a growth delay of 3.2 in comparison to the
control.
Patient DD had a Stage II ovarian carcinoma
diagnosed in 1978, received chlorambucil for 1 year
when repeat surgery revealed no residual disease.
Two years later a paracolic tumour mass was
completely resected and the xenograft line
established from a sample of this tumour.
Cisplatinum and chlorambucil were then given for 1
year and she remains in complete remission
(documented surgically) 2 years after completing
treatment. In the xenografted line there was a
complete regression with cisplatinum (6/8 tumours)
and melphalan (10/10 tumours) with no evidence of
regrowth occurring during the period of
observation of 10 weeks. This sensitivity to
melphalan is of interest as it is quite possible that
the recurrent tumour could have developed from a
resistant subpopulation of the original tumour and
therefore be resistant to alkylating agents.
Patient JC was treated with cisplatinum and
chlorambucil and after an initial brief partial
response rapidly developed progressive drug
resistant disease. A xenograft was established from
ascitic fluid which was tapped for symptomatic
relief when the patient was pre-terminal. The
tumour established in the mice had a paradoxical
response as growth delay occurred with both
cisplatinum (2.5) and melphalan (1.4). Xenograft
morphology and ploidy were similar to those of the
original tumour.
Patients GGI and JN had recurrent carcinoma
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that had become resistant to cisplatinum and mel-
phalan. Ascitic fluids were aspirated for symptoma-
tic relief and both tumours were established in nude
mice from cells passaged in tissue culture flasks.
The xenografted GG1 exhibited a similar response
to the original tumour, with minimal growth delay
occuring with cisplatinum (1.1) and melphalan
(0.87). JN xenograft however, was markedly sensit-
ive to cisplatinum with complete regression occurr-
ing in 8 of 10 tumours, but was resistant to
melphalan.
Five of the lines (DD, JV1, JN, NF, GG1) were
retreated in subsequent passages and maintained
their sensitivity/resistance to cisplatinum and mel-
phalan. The results of these studies suggest that
tumours may retain a similar degree of therapeutic
responsiveness as occurs in the patient, particularly
if the xenograft was established directly from the
original tumour and not propagated initially in
tissue culture. However, discordant responses were
observed at times.
DNA content andproliferative activity (Sphase) of
Xenografted tumours
Flow cytometric analysis of DNA content was
studied sequentially in eleven tumours established
directly in nude mice and repeated in subsequent
passages. Results outlined in Table V demonstrate
that the DNA Index (DI) and S phase fraction
remain essentially unchanged following serial
passage. Mean variation of the DI before and after
passage in nude mice was 5% (range 0-10%), a
result consistent with staining and instrumental
variation (Taylor & Milthorpe, 1980). It should be
noted, however, that in one particular tumour
GGI), a spontaneous and persistant change in
tumour DNA content was observed in a castrated
male mouse. Initially the tumour had a DI of 1.7
which increased to a DI of 2.8. The growth rate of
the tumour before and after the change was similar
and a kinetic advantage for the new cells was not
apparent. This new tumour (designated GG2) has
remained stable over 9 further transplant gener-
ations and has a human karyotype (modal chromo-
some number of 110). It exhibits similar antigenic
expression to the original tumour being CA1 and
EMA positive and OC125, CEA and AFP negative.
The S phase fraction may vary within different
areas of ovarian tumours, possibly due either to
variable contamination of tumour cells by normal
non-cycling cells or to altered proliferative states of
tumour cells in different nutritional environments.
The variability in S phase fraction was studied in
three xenograft lines after injecting the mice with
Lissamine green. The S phase fraction was consist-
ently higher in well vascularised areas of a tumour
compared with poorly vascularised areas (Figure 4).
Establishment ofa model system to investigate
tumourploidy
Aneuploid tumours have a high take rate in nude
mice in contrast to diploid tumours. Only one
diploid line (FF) was established, from a patient
with a StageIa endometrioid ovarian carcinoma.
This tumour has remained diploid through 3
passages and the histological appearance is similar
to that of the original (donor) tumour. It grew very
slowly, with a doubling time (area) of 30-35 days
and a latent time of 12 weeks following implant-
ation before it became measurable (- 3 mm in
diameter). The transplant take rate is only 50% and
spontaneous regressions of the tumour have been
noted occasionally (<5% of tumours).
Table V Comparison of ploidy and S phase of parent tumour and xenograft
Original tumour Xenograft Number of
Tumour DI S phase % DI S phase % passages
EH 1.64 16.9 1.73 18.2 4
CC 2.60 25 2.53 21.1 2
JV 0.86 - 0.92 10.2+2.6 6
HP 1.45 25 1.6 22.8+3.7 4
JC 1.35 1.41 18.5+2 3
DD 1.9 25 1.92 23.2+3 5
PP 2 21.5 2 22.2+5 5
NF 1.47 24.7 1.52 25.6+2.8 6
FF 1 15 1 12.3+2.5 3
DO 1.33 21.8 1.42 22.8+2 3
JM 1.72 16.8 1.9 23.8+5.1 3
Table contains data on xenografted tumours established directly from patient.OVARIAN TUMOUR XENOGRAFTS 329
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Figure 4 DNA histograms from 3 different ovarian tumour lines growing in nude mice injected with
Lissamine green. Note the higher S phase obtained in the well vascularised (green) areas compared to the
poorly vascularised (white) areas of the tumour.
The influence of quantitative differences of
tumour cell DNA content on biological behaviour,
was investigated by attempting to establish xeno-
grafted tumours with common ancestry yet differ-
ent degrees of aneuploidy (Figure 5). JVI is a
serious tumour with a DI of 0.86 that was es-
tablished directly in the mouse, while JV2 was
inoculated in nude mice from cells obtained after
the original tumour had been grown in tissue
culture for 14 passages. The latter cells exhibited a
doubling of DNA content in the third passage in
vitro and have remained stable thereafter (DI= 1.5).
JV2 had a modal number of 64 chromosomes prior
to implantation. The JV2 xenograft line is less well
differentiated than JVl but is still serous in type
and expresses the same surface antigens as JV1 (see
Table III). The two lines have quite different re-
sponses to chemotherapy, as described earlier.
Another model exists in the GG xenograft line
where GGI is an aneuploid (DI= 1.7) clear cell
carcinoma initially established in nude mice after
being propagated in tissue culture and GG2 is a
variant (DI=2.8) that arose spontaneously follow-
ing the implantation of GGl in a castrated male
mouse. These lines have a human karyotype and
the ploidy has remained stable over 10 subsequent
passages. Both lines are EMA and CA1 positive,
OC125 negative and histologically poorly different-
iated. GG2 differs from GGI in being relatively
sensitive to cisplatinum but both lines are resistant
to melphalan.
Discussion
Attempts have been made to establish a series of
epithelial ovarian tumours in congenitally athymic
mice to investigate their biological characteristics
and to determine whether they provide a suitable
model of human ovarian cancer. The extent to
which a human tumour xenograft reflects and
maintains the properties of the original source
tumour is an essential feature favouring the use of
xenografts over that of syngeneic animal tumours
as models of human cancer. In this study, xeno-
grafted tumours have been compared with the
original tumour with respect to their morphological
features, cell surface markers, cellular DNA cont-
ent, proliferative fraction and where possible, thera-
peutic responsiveness. The results indicate good
correlation in such characteristics as morphology,
surface antigen expression and cellular DNA cont-
ent between parent and xenografted tumour. These
findings are in keeping with those reported in a
number of other tumour types (Povlsen et al., 1975;
Reeves et al., 1978; Raghavan et al., 1980, 1981;
Giovanella et al., 1983). The majority of success-
fully implanted tumours were poorly differentiated
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Figure 5 DNA histograms of ovarian carcinoma xenografts demonstrating the different ploidies obtained
from the same tumour. JV1, established directly from the patient and JV2 established as a xenograft after the
tumour was propagated in tissue culture for 14 passages. GG1, established as a xenograft after 10 passages in
culture and GG2 exhibits the change in ploidy that occurred spontaneously when GG1 was growing in a
castrated male mouse.
initially and have remained so. Three moderately
differentiated (Grade 2) tumours have maintained
their degree of differentiation following xenograft-
ing but they have been through relatively few
passages and it remains to be seen whether this will
continue over longer periods of time.
The xenografted tumour functions that remain
stable during serial transplantation include the con-
tinued production of melanin in melanomas
(Povlsen, 1976), CEA in colorectal carcinomas
(Houghton & Taylor, 1978), ,BHCG in choriocarci-
nomas (Kim et al., 1978) and AFP in teratomas
(Raghavan et al., 1981). Relatively little has been
previously published on the expression of cell sur-
face antigens and tumour marker production in
epithelial ovarian tumour xenografts and the curr-
ent series demonstrates the consistency in the ex-
pression of two differentiation antigens (EMA and
CA125) and a putative human cancer specific anti-
gen (CA antigen) in xenografted tumours and their
original source tumours. There is some controversy
regarding the incidence of CEA and AFP positivity
in ovarian epithelial ovarian tumours (for review
see Raghavan et al., 1984). The absence of CEA in
all xenografts as well as failure to demonstrate AFP
in all but one tumour (in which only a few isolated
cells stained), correlated with the findings in the
original tumour and is in keeping with the majority
of reports of tumour marker production in ovarian
epithelial neoplasms.
As we have reported previously, the cellular
DNA content remained stable during serial passage
of ovarian tumour xenografts and in all but one,
case closely resembled that of the original tumour
(Friedlander et al., 1984d). This confirms the find-
ings of DNA content and karyotypic stability noted
in other xenografted tumour types (Povlsen &
Jacobson, 1975, Povlsen et al., 1982; Linderberger,
1981; Tilgen et al., 1983) and contrasts with observ-
ations in tissue culture that changes in DNA cont-
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ent and modal chromosomal number are common
(Van Haaften Day et al., 1983; Bigner et al., 1984).
The reasons for this variability in ploidy are not
clear, but the finding that similar changes take
place when "normal" mouse keratinocytes are
grown in tissue culture, (particularly in the presence
of low calcium concentrations in the medium) sug-
gests that changes in cell physiology following the
adaption to growth in culture are reflected in, or
even caused by genetic alterations (Fusenig et al.,
1982). This genetic instability is a limitation of the
in vitro model system. The apparent difference in
the biological behaviour of diploid and aneuploid
tumours noted in the clinical setting therefore re-
quire a suitable in vivo model to facilitate further
study. The S phase fraction has been previously
reported to vary within different regions of
epithelial ovarian tumours (Friedlander et al.,
1984d). This variability was also evident in xeno-
grafted tumours, the S phase fraction being higher
in well vascularised areas compared with poorly
vascularised areas. These findings are consistent
with those of Selby et al. (1979) who found that
labelling indices were similar in donor and xeno-
graft tumours, but cells at the periphery had a
higher labelling index than those in the central
region.
It has been suggested that the most precise and
relevant way of validating the xenograft system for
therapeutic purpose is to directly compare xeno-
graft response with the clinical response of the
donor patient (Steel et al., 1983). However apart
from the fact that the pharmacokinetics of antican-
cer drugs in tumour-bearing mice are poorly under-
stood, there are also difficulties relating to the
scheduling of treatment and the method of quant-
itating tumour response. Tumour growth delay can
be influenced by such factors as the dosage and
scheduling of drugs used, the site of the tumour
and the immune response (Steel & Peckham, 1980;
Warenius et al., 1980). These problems are reflected
in the results of therapeutic testing where at times a
discordant therapeutic response between patient
and xenografted tumour was seen. It was possible
to compare response to chemotherapy of 7 xeno-
grafted tumours with that of the patient from
which the xenografts were derived. In 4 instances
there was a good correlation between responses
observed while in 3 cases the results of treatment
were somewhat different. The latter included; one
patient who had no evidence of tumour following
treatment with cisplatinum and cyclophosphamide
yet the xenograft exhibited only minimal growth
delay with cisplatinum and melphalan; one patient
with a tumour clinically resistant to cisplatinum
and chlorambucil, the growth of which in nude
mice was temporarily inhibited during therapy but
regrew rapidly after treatment; and one patient
whose tumour was clinically resistant to cisplatinum
and chlorambucil but where the xenograft respon-
ded completely to cisplatinum. There were some
differences however, in the treatment of patients
and xenografts as only single agents at the max-
imum tolerated dose were used in the xenograft
system while patients usually received combination
chemotherapy. Furthermore, the bulk of tumour
present in patients differed from that in xenografts,
a factor which may influence response to treatment.
Two of the three ovarian tumour lines
propagated in tissue culture prior to being
established as xenografts responded to therapy
differently to that seen in the patient. It is
conceivable that the genotypic and phenotypic
changes which occur during cell culture could
account for this difference. It has been previously
claimed that xenografts may be useful in the
selection of appropriate chemotherapy of individual
patients (Giovanella et al., 1983). However, the
relatively low take rates, the long delay between
establishing and subsequently testing xenografts,
and the not uncommon paradoxical results seen
with treatment would appear to preclude
xenografted tumours having a predictive role in the
choice of treatment for individual patients. In the
therapeutic setting, the place of ovarian xenografts
may be rather the primary screening of new drugs
and testing novel experimental approaches to
treatment such as hormonal therapy or the
Mullerian Inhibitory Substance.
The major differences between xenografted and
human ovarian tumours include the very low
incidence of metastases in nude mice, and a tumour
doubling time (mean= 14 days) that is far more
rapid than already seen clinically (Steel & Peckham,
1980). The reasons for these differences are not
known but it has been postulated that tumours that
grow in mice are either selected for rapid growth or
increase their growth rate in the new environment.
Although the S phase and labelling indices are
slightly higher in the xenografted tumour than in
the original tumour, the differences are not large
enough to explain the differences in doubling time,
and a decreased cell loss factor may be important
contributing factor (Rofstadt et al., 1982). In
addition, the xenograft model is a highly selective
system which favours growth of tumours that in
most instances are aggressive, aneuploid, poorly
differentiated and disseminated at the time of
diagnosis. These selection pressures make this
model system unsuitable for investigating the
biology of the whole spectrum of ovarian epithelial
tumours. Only one diploid line from a patient with
a Stage Ia ovarian cancer was established. While it
is possible that this line may be a useful model for332 M.L. FRIEDLANDER, et al.
further study the fact that it grows as a xenograft
may indicate that it is biologically different to the
group of diploid ovarian tumours previously
reported to have a relatively good prognosis.
Further attempts to establish "biologically indolent"
tumours are warranted as there are reports in other
tumour types of benign and low grade tumours
being successfully implanted (McManus et al.,
1978).
In conclusion, the findings of this study suggest
that ovarian tumour xenografts, in general, reflect
the biological characteristics of the tumours from
which they are derived. Notwithstanding the
number of limitations, tumour xenografts will be a
useful model for exploring some of the biological
properties of human ovarian cancer. Possible
directions for future studies using xenografts
include investigation into the degree of genetic
instability, mutation rate, oncogene expression and
acquisition of drug resistance in xenograft lines
established from tumours that vary in their clinical
behaviour.
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